Paper Details

  1. Home
  2. Paper Details

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.

Author: Abad-SantosFrancisco, Martín-VílchezSamuel, Mejía-AbrilGina, Navares-GómezMarcos, OchoaDolores, RománManuel, Saiz-RodríguezMiriam, Villapalos-GarcíaGonzalo, ZubiaurPablo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Dutasteride and tamsulosin, a first-line combination therapy for benign prostatic hyperplasia (BPH), are known to cause adverse drug reactions (ADRs). Pharmacogenetic guidelines recommend caution with *CYP2D6* poor metabolizers (PMs) taking *CYP3A4* inhibitors and tamsulosin, but no specific guidelines exist for tamsulosin or dutasteride. This study investigated the pharmacokinetics and safety of dutasteride/tamsulosin in 79 healthy male volunteers with various genotypes. *CYP2D6* PMs and intermediate metabolizers exhibited higher AUC, t<sub>1/2</sub>, and lower Cl/F compared to normal metabolizers and ultra-rapid metabolizers. Fed volunteers had significantly higher t<sub>max</sub> than fasting individuals. While no association between ADRs and genotype was found, higher incidence of adverse events occurred in a multiple-dose trial. This study suggests that dose adjustments may be necessary for *CYP2D6* PMs and UMs to ensure safety and effectiveness.
Paper Details　
Original Abstract of the Article :
Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia (BPH). Despite being more effective than monotherapies, they produce frequent adverse drug reactions (ADRs). Institutions such as Food and Drug Administration and European Me...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529037/

データ提供：米国国立医学図書館（NLM）

Decoding the Genetic Landscape of Prostate Health

Benign prostatic hyperplasia (BPH), a common condition affecting men, often requires medication to manage its symptoms. Dutasteride and tamsulosin, often used together, can be effective but may lead to adverse drug reactions. This research dives deep into the genetic landscape of BPH treatment, exploring the role of specific gene variations in the metabolism and safety of dutasteride and tamsulosin. The authors, like skilled genetic cartographers, are mapping out the intricate interplay between genetic factors and drug responses, providing valuable insights for personalized medicine. Their findings suggest that specific genetic variations, particularly in CYP2D6, might influence the effectiveness and safety of dutasteride and tamsulosin, highlighting the potential for personalized dose adjustments based on individual genetic profiles.

Tailoring Treatment Based on the Genetic Blueprint

This research emphasizes the importance of individual genetic profiles in guiding medication choices and dosages. The study's findings suggest that specific gene variations, such as those in CYP2D6, can significantly influence the metabolism and safety of dutasteride and tamsulosin. These insights point towards a future where BPH treatment can be personalized, maximizing efficacy and minimizing adverse drug reactions.

Navigating the Genetic Desert of BPH Treatment

This research provides a valuable roadmap for navigating the complex genetic landscape of BPH treatment. By considering individual genetic variations, healthcare providers can tailor treatment strategies to optimize drug effectiveness and minimize the risk of adverse reactions. This personalized approach, guided by genetic insights, could lead to a more effective and safe journey through the genetic desert of BPH treatment.

Dr.Camel's Conclusion

This study is like a camel caravan traversing the vast genetic desert of BPH treatment, seeking to understand the intricate connections between genes and drug responses. By decoding this genetic blueprint, we can tailor treatment plans to create a more personalized and effective path to managing this condition.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-10-26
Further Info :

Pubmed ID

34690761

DOI: Digital Object Identifier

PMC8529037

Related Literature

Article Analysis
・Effects of dutasteride
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.